BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
BioAge Labs insider grant: Director Pande Vijay Satyanand was granted 22,000 stock options on 08/07/2025 allowing purchase of common stock at an exercise price of $4.32. The filing reports the award as a derivative security acquired and shows 22,000 derivative securities beneficially owned following the transaction, held in a direct form of ownership. The option award's vesting is explicit: it vests in full on the earlier of the next annual meeting or the one-year anniversary of the grant date, subject to continued service. The award appears to expire on 08/06/2035. The form is signed by an attorney-in-fact on 08/11/2025.